Last Updated on September 17, 2026
What’s the success rate of medication-assisted treatment for opioid addiction in Texas? Research shows that medication-assisted treatment (MAT) reduces opioid overdose deaths by 38 to 50 percent and increases retention in treatment programs by 50 to 75 percent compared to behavioral therapy alone. In Texas, where opioid-related overdose deaths exceeded 2,400 in recent years, these numbers translate to measurable lives saved. MAT combines FDA-approved medications—buprenorphine, methadone, or naltrexone—with counseling and behavioral therapies to treat opioid use disorder comprehensively.
If you or someone you love needs more than detox, Nova Recovery Center also provides inpatient rehab austin.
Nova Recovery Center’s drug and alcohol treatment program provides medically supervised, evidence-based care.
How Success Is Measured in Medication-Assisted Treatment Programs
Success in MAT isn’t a single number. Clinical trials and treatment centers measure multiple outcomes: sustained abstinence from illicit opioids, retention in treatment beyond 90 days, reduced criminal activity, improved employment rates, and decreased overdose deaths. A patient who completes six months of buprenorphine treatment with weekly counseling and remains in recovery has a fundamentally different trajectory than someone who attempts detox alone and relapses within days.
Texas-specific data from the Department of State Health Services indicates that patients enrolled in MAT programs show a 60 percent reduction in illicit opioid use at six months. Retention matters: patients who stay in treatment for at least 12 months have relapse rates comparable to other chronic diseases like hypertension or diabetes—roughly 40 to 60 percent, which is lower than the 80 to 90 percent relapse rate seen with detox-only approaches.
At Nova Recovery Center’s Austin, Houston, and San Antonio outpatient locations, MAT is integrated into structured programming that includes individual therapy, group counseling, and medical monitoring. The combination addresses both the neurochemical dependence and the behavioral patterns that sustain addiction.
The Three Medications Approved for Opioid Use Disorder
Understanding what drives the success rate of medication-assisted treatment for opioid addiction in Texas requires clarity on the medications themselves. Each works differently and fits different clinical situations.
Buprenorphine is a partial opioid agonist that reduces cravings and withdrawal without producing euphoria. It’s dispensed in outpatient settings, allowing patients to maintain work and family responsibilities. Studies show 49 to 74 percent of patients remain in treatment at 12 months when buprenorphine is combined with counseling. It’s the most commonly prescribed MAT medication in Texas outpatient programs.
Methadone is a full opioid agonist dispensed daily at federally regulated clinics. It has the longest track record—over 50 years of research—and shows retention rates of 60 to 80 percent at one year. Methadone is effective for patients with severe, long-duration opioid dependence, though the daily clinic requirement limits flexibility.
Naltrexone (especially the extended-release injectable form, Vivitrol) is an opioid antagonist that blocks the euphoric effects of opioids. It requires complete detoxification before initiation, which creates a barrier for some patients. However, patients who successfully start naltrexone show relapse rates 17 percent lower than placebo in controlled trials.
Why Medication-Assisted Treatment Outperforms Detox Alone
Opioid use disorder is a chronic brain disease. Long-term opioid exposure alters the brain’s reward circuitry, stress response, and executive function. Detoxification addresses physical dependence but does nothing to repair these neurological changes. Withdrawal ends, cravings persist, and relapse follows—often within days or weeks.
MAT medications normalize brain chemistry. Buprenorphine and methadone stabilize opioid receptors, reducing the intense cravings and dysphoria that drive relapse. Naltrexone prevents relapse by making opioid use ineffective. This pharmacological stabilization gives patients the neurological foundation to engage in therapy, rebuild routines, and develop coping skills.
The data is unambiguous. A 2020 study in JAMA Psychiatry followed over 83,000 patients and found that those on buprenorphine or methadone had overdose death rates 50 percent lower than those not on medication. In Texas, where fentanyl-contaminated heroin and counterfeit pills drive overdose mortality, that difference is life or death.
Success Rates Vary by Treatment Intensity and Duration
What’s the success rate of medication-assisted treatment for opioid addiction in Texas when comparing inpatient versus outpatient settings? Both are effective, but outcomes improve when medication is paired with sufficient clinical intensity.
Inpatient or residential MAT—available at Nova Recovery Center’s Austin and Wimberley, Texas, locations—provides 24-hour medical supervision, daily therapy, and a controlled environment free from triggers. Patients stabilize on medication while building a foundation of behavioral skills. Research shows that completing 30 to 90 days of residential treatment followed by outpatient MAT increases one-year abstinence rates to 55 to 65 percent.
Outpatient MAT—offered at Nova’s Austin, Houston, San Antonio, and Colorado Springs locations, as well as online through telehealth IOP—allows patients to remain in their communities. Intensive outpatient programs (IOP) deliver nine or more hours of therapy per week while patients receive medication management. Completion rates for outpatient MAT range from 50 to 70 percent when programs exceed six months.
Duration matters as much as intensity. Patients who remain on buprenorphine or methadone for two years or longer show sustained remission rates above 60 percent. Early discontinuation—often driven by stigma, insurance barriers, or pressure from non-MAT-informed providers—dramatically increases relapse risk.
Addressing Barriers to Medication-Assisted Treatment in Texas
Despite proven effectiveness, MAT remains underutilized. Only about 20 percent of Texans with opioid use disorder receive any form of treatment, and fewer than half of those receive medication. Barriers include stigma, lack of trained prescribers, insurance coverage gaps, and misinformation about “trading one drug for another.”
Stigma persists even among healthcare providers. Some treatment programs still promote abstinence-only models, incorrectly framing MAT as incomplete recovery. This is contradicted by every major medical organization—the American Medical Association, the American Society of Addiction Medicine, and the National Institute on Drug Abuse all recognize MAT as the standard of care for opioid use disorder.
Texas has expanded access in recent years. The state increased the number of buprenorphine-waivered prescribers and implemented Medicaid coverage for all three MAT medications. Private insurance networks now include more MAT providers, though out-of-pocket costs and prior authorization requirements remain obstacles for some patients.
Nova Recovery Center’s outpatient locations in Austin, Houston, and San Antonio accept most major insurance plans and verify benefits before admission. Payment plans and financing options address cost concerns without compromising care quality.
What Happens After Medication-Assisted Treatment Stabilization
Stabilization is the beginning, not the endpoint. Patients typically remain on medication for 12 to 24 months minimum, often longer. During this period, therapy addresses trauma, co-occurring mental health disorders, relationship repair, and relapse prevention skills.
Some patients taper off medication after two or more years of stability. Others continue indefinitely, treating opioid use disorder as a chronic condition requiring long-term management—similar to insulin for diabetes or antidepressants for depression. Research supports both approaches; the key is individualized decision-making based on relapse risk, patient preference, and clinical judgment.
Continuing care after formal treatment ends improves outcomes. Alumni programs, peer support groups, and periodic check-ins with prescribers help patients navigate challenges. Nova’s outpatient structure allows for step-down care: patients transition from intensive outpatient to standard outpatient to monthly medication management as their recovery strengthens.
Choosing a Program That Integrates Medication and Therapy
What’s the success rate of medication-assisted treatment for opioid addiction in Texas when behavioral therapy is omitted? Significantly lower. Medication alone improves outcomes compared to no treatment, but the combination of medication and counseling produces the best results.
Effective MAT programs include:
- Medical evaluation and medication induction supervised by addiction medicine physicians or nurse practitioners
- Individual therapy addressing underlying trauma, co-occurring disorders, and relapse triggers
- Group counseling providing peer support and skills training
- Toxicology monitoring to track progress and identify early relapse
- Care coordination connecting patients to housing, employment, legal, and family services
Programs that treat opioid addiction as a purely pharmacological problem miss the psychological, social, and environmental factors that sustain use. Medication provides neurological stability; therapy rebuilds the life.
If you or someone you’re responsible for is facing opioid addiction, Nova Recovery Center’s Texas locations in Austin, Houston, and San Antonio offer medication-assisted treatment integrated with evidence-based therapy in both inpatient and outpatient settings.
Ready to take the next step?
Nova Recovery Center provides inpatient and outpatient drug & alcohol rehab. Call (512) 893-6955 to speak with our team today.
